Tension between practitioners who believe autologous stem cells should be considered a service and the FDA, which considers some of them biologics, has come to a head in recent months. Laura DeFrancesco investigates.
References
Lysaght, T. & Campbell, A.V. Cell Stem Cell 9, 393–396 (2011).
Powell, R.J. et al. Mol. Ther. 20, 1280–1286 (2012).
DeFrancesco, L. Nat. Biotechnol. 30, 379 (2012).
Koleva, G. Stem Cells, FDA, and the edge of science: three expert viewpoints. Forbes, 10 February 2012. http://www.forbes.com/sites/gerganakoleva/2012/02/10/stem-cells-and-the-lawsuit-that-may-shape-our-medical-future/
Cuende, N., Rico, L. & Herrera, C. Stem Cells Transl. Med. 1, 403–408 (2012).
Gir, P. et al. Plast. Reconstr. Surg. 129, 1277–1290 (2012).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
DeFrancesco, L. Adult stem cell therapies walk the line. Nat Biotechnol 30, 739–741 (2012). https://doi.org/10.1038/nbt.2321
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.2321
- Springer Nature America, Inc.